Literature DB >> 25212894

Are OPG and RANKL involved in human fracture healing?

Julia Köttstorfer1, Anita Thomas, Markus Gregori, Mathias Kecht, Georg Kaiser, Stefan Eipeldauer, Kambiz Sarahrudi.   

Abstract

Human fracture healing is a complex interaction of several cytokines that regulate osteoblast and osteoclast activity. By monitoring OPG (osteoprotegerin) and sRANKL we aimed to possibly predict normal or impaired fracture healing. In 64 patients with a fracture of a long bone serum level of sRANKL and OPG were evaluated with respect to bony union (n=57) or pseudarthrosis (n=7). Measurements were carried out at admission and at 1, 2, 4, 6, 8, 12, 24, and 48 weeks after the injury. Patients' serum levels were compared to 33 healthy controls. Fracture hematoma contained significantly higher sRANKL and OPG concentrations compared to patients serum (p=0.005, p=0.028). OPG level in fracture hematoma was higher compared to the unions serum level (p=0.028). sRANKL was decreased in unions during the observation period. In non-unions sRANKL and OPG levels showed a variable course, with no statistical significance. This is the first study to document the course of OPG and sRANKL in normal and delayed human fracture healing emphasizing its local and systemic involvement. We provide evidence of strongly enhanced OPG levels in patients with a long bone fracture compared to healthy controls. Further, levels of free sRANKL were decreased during regular fracture repair.
© 2014 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.

Entities:  

Keywords:  OPG; RANKL; fracture healing

Mesh:

Substances:

Year:  2014        PMID: 25212894     DOI: 10.1002/jor.22723

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  7 in total

1.  Serum levels of the bone turnover markers dickkopf-1, sclerostin, osteoprotegerin, osteopontin, osteocalcin and 25-hydroxyvitamin D in Swedish geriatric patients aged 75 years or older with a fresh hip fracture and in healthy controls.

Authors:  P Wanby; R Nobin; S-P Von; L Brudin; M Carlsson
Journal:  J Endocrinol Invest       Date:  2016-02-05       Impact factor: 4.256

2.  Effects of Local Antibiotic Delivery from Porous Space Maintainers on Infection Clearance and Induction of an Osteogenic Membrane in an Infected Bone Defect.

Authors:  Sarita R Shah; Brandon T Smith; Alexander M Tatara; Eric R Molina; Esther J Lee; Trenton C Piepergerdes; Brent A Uhrig; Robert E Guldberg; George N Bennett; Joseph C Wenke; Antonios G Mikos
Journal:  Tissue Eng Part A       Date:  2017-01-11       Impact factor: 3.845

Review 3.  [Progress of research on the relationship between calcitonin gene-related peptide and RANK/RANKL/OPG system in the bone reconstruction].

Authors:  Shiyao Wang; Shaoce Xu; Zhengwei Shi; Jianchao Wu; Shuanhu Lei; Yuliang Wang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2019-04-15

4.  Effects of tendon-bone healing of anterior cruciate ligament reconstruction by osteoprotegerin combined with deproteinized bovine bone.

Authors:  Guoyao Zou; Enhong Song; Bing Wei
Journal:  Muscles Ligaments Tendons J       Date:  2017-09-18

5.  Changes of Bone Turnover Markers in Long Bone Nonunions Treated with a Regenerative Approach.

Authors:  Donatella Granchi; Enrique Gómez-Barrena; Markus Rojewski; Philippe Rosset; Pierre Layrolle; Benedetta Spazzoli; Davide Maria Donati; Gabriela Ciapetti
Journal:  Stem Cells Int       Date:  2017-06-20       Impact factor: 5.443

6.  The impact of nonosteogenic factors on the expression of osteoprotegerin and RANKL during human fracture healing.

Authors:  Julia Starlinger; Georg Kaiser; Anita Thomas; Kambiz Sarahrudi
Journal:  Bone Joint Res       Date:  2019-08-02       Impact factor: 5.853

7.  Direct comparison of 3D and 2D cultivation reveals higher osteogenic capacity of elderly osteoblasts in 3D.

Authors:  Stephan Payr; Elizabeth Rosado-Balmayor; Thomas Tiefenboeck; Tim Schuseil; Marina Unger; Claudine Seeliger; Martijn van Griensven
Journal:  J Orthop Surg Res       Date:  2021-01-06       Impact factor: 2.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.